Careers  |  Sign In  |  Register  |   Twitter

Content Hub: All Things Movement Disorders

Investigational Therapy Aims to Block Toxic α-Synuclein Propagation

PRX002, a monoclonal antibody against α-synuclein, is being developed by Prothena in collaboration with Roche. Misfolded and aggregated α-synuclein is strongly implicated in Parkinson’s disease. The protein is believed to spread among neurons in the brain, driving disease progression.

Current treatments for PD only address symptoms, such as motor impairment and psychosis; none modifies the disease course. If ongoing trials of PRX002/RG7935 are successful, patients with PD who are diagnosed early could benefit from a treatment that may prevent the neurodegeneration associated with α-synuclein misfolding and/or cell-to-cell transmission.

Recent Study Reveals Association Between Asymmetry of Drug-Induced Parkinsonism and Severity of Psychiatric Disease

PRX002 is an investigational antibody against α-synuclein as a disease-modifying therapy that stops the misfolding of α-synuclein and/or the spread of its aggregates in the brain. MORE

Smartphone App to Help Parkinson’s Disease Patients Overcome Freezing of Gait

PRX002 is an investigational antibody against α-synuclein as a disease-modifying therapy that stops the misfolding of α-synuclein and/or the spread of its aggregates in the brain. MORE

Researchers Say Parkinson’s Drug Needs Longer-Term "Home"

PRX002 is an investigational antibody against α-synuclein as a disease-modifying therapy that stops the misfolding of α-synuclein and/or the spread of its aggregates in the brain. MORE